LIMITED OFFER
Save 50% on book bundles
Immediately download your ebook while waiting for your print delivery. No promo code needed.
Side Effects of Drugs Annual
- 1st Edition, Volume 46 - November 20, 2024
- Editor: Sidhartha D. Ray
- Language: English
- Hardback ISBN:9 7 8 - 0 - 4 4 3 - 2 9 4 4 6 - 4
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 2 9 4 4 7 - 1
Side Effects of Drugs Annual: A Worldwide Yearly Survey of New Data in Adverse Drug Reactions, Volume 46, first published in 1977, presents clinicians and medical investiga… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteSide Effects of Drugs Annual: A Worldwide Yearly Survey of New Data in Adverse Drug Reactions, Volume 46, first published in 1977, presents clinicians and medical investigators with a critical survey of new data and trends in adverse drug reactions and interactions. Topics covered include ADRs, ADEs and SEDs: A Bird’s Eye View, Lithium, Drugs of abuse, Side effects of drugs used in the treatment of Alzheimer's disease, Sedatives and hypnotics, Antipsychotic agents, Anti-epileptic Medications, Side effects of opioid analgesics and narcotic antagonists, Anti-inflammatory and antipyretic analgesics and drugs used in gout, Side effects of local anesthetics and therapeutic gases, and more.
Other sections covered include Antihistamines (H1 receptor antagonists), Drugs that act on the respiratory tract, Positive inotropic drugs and drugs used in dysrhythmias, Beta adrenergic antagonists and antianginal drugs, Drugs acting on the cerebral and peripheral circulations, Antihypertensive drugs, and much much more.
- Provides a critical yearly survey of the new data and trends regarding the side effects of drugs
- Authored and reviewed by worldwide pioneers in the clinical and practice sciences
- Presents an essential clinical guide on the side effects of drugs for practitioners and healthcare professionals alike
Pharmacologists; clinicians; pharmaceutical companies; clinical toxicologists; clinical pharmacologists and medical libraries
- Side Effects of Drugs Annual, 46
- Cover image
- Title page
- Table of Contents
- Copyright
- Contributors
- Preface
- Special Reviews in SEDA 46
- Table of Essays, Annuals 1–45
- Abbreviations
- Analysis of ADRs, ADEs, drug interactions, toxicity and side effects of drugs in the shadow of vaccines, drug-antibody conjugates and pharmacogenomics
- Abstract
- Keywords
- Introduction
- Analysis of ADEs, ADRs, side effects and toxicity
- Terminology
- EIDOS
- DoTS
- WHO classification
- References on adverse drug reactions
- Further reading
- Pharmacogenomic considerations
- Enzymes and transporters
- Human leukocyte antigens (HLA)
- Pharmacogenetic testing
- Resources for pharmacogenetic information
- Conclusion
- References
- Further reading
- Immunological/hypersensitivity reactions
- Type I reactions (IgE-mediated anaphylaxis; immediate hypersensitivity)
- Type II reactions (cytotoxic reactions)
- Type III reactions (immune-complex reactions)
- Type IV reactions (cell-mediated or delayed hypersensitivity reactions)
- Other types of reactions
- References
- Vaccine-induced adverse effects
- Special Review
- References
- Analysis of toxicological reactions
- Potentiation reactions
- Synergistic effect
- Additive effect
- Antagonistic effects
- Cross references
- Antibody-drug conjugates
- Tumors being targeted
- Target antigen
- Linker type used in the ADCs
- Cytotoxic drugs (payloads)
- Development of resistance to ADCs
- Conclusion
- References
- Grades of adverse drug reactions
- Reference
- FDA pregnancy categories/classification of teratogenicity
- Category A
- Category B
- Category C
- Category D
- Category X
- Category N
- References [Clinicians are suggested to be aware of the information contained in the following literature originating from regulatory agencies; Readers are advised to follow the most up-to-date info posted on respective websites prior to advising patients]
- Conclusion
- Acknowledgement
- Chapter 1 Side effects of antidepressant use in pregnancy
- Abstract
- Keywords
- Introduction
- The physiology of placental drug transfer
- The mechanism of selective serotonin reuptake inhibitors (SSRIs) and its effects on the pregnant patient
- Preeclampsia
- Emotional regulation in offspring
- Gestational diabetes
- Selective serotonin reuptake inhibitors (SSRIs) and its effects on the fetus
- Autism Spectrum disorder
- ADHD
- Serotonin and norepinephrine reuptake inhibitors (SNRIs)
- Common mood stabilizers
- Special note of alternative treatments for depression
- Conclusions
- References
- Chapter 2 Side effects of Lithium: Recent case studies on its adverse effects
- Abstract
- Keywords
- Introduction
- Cardiovascular
- Endocrine
- Nervous system
- Drug interactions
- Conclusions
- References
- Chapter 3 Drugs of abuse
- Abstract
- Keywords
- Introduction
- Prescription drugs
- Opioids, opioid derivatives, and opioid-like agents
- CNS depressants
- CNS stimulants
- Illicit drugs
- Opioids and synthetic/semi-synthetic opioids
- Synthetic CNS depressants, and designer benzodiazepines
- Stimulants, synthetic stimulants, and combinations containing stimulants
- Cannabis, CBD, synthetic cannabis, and combinations including synthetic cannabis
- Over the counter (OTC) drugs
- Nicotine
- Loperamide
- Conclusion
- References
- Chapter 4 Recent perspectives on side effects of drugs used in the treatment of Alzheimer's disease
- Abstract
- Keywords
- Introduction
- Acetylcholinesterase inhibitors
- Rivastigmine
- Donepezil
- Galantamine
- NMDA antagonist
- Memantine
- Anti-amyloid antibodies
- Aducanumab
- Lecanemab
- Donanemab
- Gantenerumab
- Brexpiprazole
- Conclusion
- References
- Chapter 5 Sedative and hypnotics
- Abstract
- Keywords
- Introduction
- Barbiturates
- Pentobarbital
- Amobarbital, butalbital, secobarbital
- Benzodiazepines
- Midazolam
- Remimazolam
- Temazepam
- Estazolam, flurazepam, nitrazepam, triazolam, quazepam
- Orexin receptor antagonists
- Daridorexant
- Lemborexant
- Suvorexant
- Melatonin agonists
- Ramelteon
- Non-benzodiazepine receptor agonists
- Eszopiclone and zopiclone
- Zaleplon
- Zolpidem
- Multiple drugs
- References
- Chapter 6 Adverse effects of antipsychotic agents
- Abstract
- Keywords
- Introduction
- First generation antipsychotics
- Second generation antipsychotics
- References
- Chapter 7 Antiseizure medications
- Abstract
- Keywords
- Introduction
- Gamma-aminobutyric acid (GABA) receptor agonists
- Clobazam
- Clonazepam
- Diazepam
- Lorazepam
- Clorazepate and phenobarbital
- GABA reuptake inhibitors
- Tiagabine
- GABA transaminase inhibitors
- Vigabatrin
- GABA analogs
- Divalproex/valproic acid/valproate
- Gabapentin
- Pregabalin
- Gabapentin and pregabalin
- Sodium channel blockers
- Carbamazepine
- Cenobamate
- Eslicarbazepine
- Lacosamide
- Lamotrigine
- Oxcarbazepine
- Phenytoin/fosphenytoin
- Zonisamide
- Glutamate blockers
- Perampenel
- Topiramate
- Miscellaneous other mechanisms of action
- Brivaracetam
- Cannabidiol
- Ethosuximide
- Ezogabine
- Felbamate
- Fenfluramine
- Levetiracetam
- Stiripentol
- Multiple drugs
- General information
- Cardiovascular: Arrhythmias
- Neuromuscular function: Movement disorders
- Neuromuscular function: Parkinson's disease
- Psychological: Cognitive impairment
- Psychiatry: Suicidality
- Urinary tract: Granulomatous interstitial nephritis
- Skin
- Hair: Alopecia
- Musculoskeletal: Vertebral fracture risk
- Immunologic: Hypogammaglobulinemia
- Second-generation effects—Pregnancy—Early abortion
- Second-generation effects: Teratogenicity
- Susceptibility factors: Genetic variants
- Drug administration: Drug administration route
- Food-drug interactions
- References
- Chapter 8 Side effects of agonists, partial agonists, and antagonists of the opioid receptor
- Abstract
- Keywords
- Introduction
- Opioid full agonists (see Fig. 1)
- Codeine
- Fentanyl
- Hydromorphone
- Methadone
- Morphine
- Oxycodone
- Tramadol
- Partial opioid agonist
- Buprenorphine
- Opioid antagonist
- Naloxone
- Naltrexone
- Conclusion
- References
- Chapter 9 Anti-inflammatory and antipyretic analgesics and drugs used in gout
- Abstract
- Keywords
- Introduction
- Aniline derivatives
- Paracetamol (acetaminophen)
- Arylalkanoic acid derivatives
- Ibuprofen
- Carboxylic acid derivatives
- Ketorolac
- Propionic acid derivatives
- Naproxen
- Pyrazole derivatives
- Celecoxib
- Salicylates
- Acetylsalicylic acid (aspirin)
- Multiple NSAID analysis
- Drugs used in the treatment of gout
- Allopurinol
- Allopurinol and febuxostat
- References
- Chapter 10 Clinical insights on adverse effects of general anaesthetics and therapeutic gases
- Abstract
- Keywords
- Ciprofol
- The effect of different doses of ciprofol in patients with painless gastrointestinal endoscopy
- Ciprofol for induction of general anesthesia in elderly patients
- Ciprofol for sedation/anesthesia in hysteroscopy
- Dexmedetomidine
- Intravenous sedation methods for MRI in children
- Dexmedetomidine and renal function
- Dexmedetomidine and ISB duration
- Dexmedetomidine and asystole in pediatric patients
- Dexmedetomidine and cerebral activity in preterm infants
- Dexmedetomidine in elderly patients undergoing hip replacement
- Dexmedetomidine and pharyngeal swallowing and esophageal motility
- Dexmedetomidine in gynecological surgeries
- Dexmedetomidine withdrawal syndrome and opioid sensitivity
- Procedural sedation for endoscopic retrograde cholangiopancreatography
- Etomidate
- Etomidate for use in septic patients
- Ketamine
- IM ketamine causes necrotic skin lesions and muscle atrophy
- Postoperative catatonia after fentanyl, hydromorphone and ketamine
- Liver profiles following prolonged ketamine administration
- Magnesium induced ketamine toxicity
- Propofol
- Postoperative delirium after dexmedetomidine vs propofol in orthopedic surgery
- Ketofol in patients with traumatic brain injury
- Unusual presentations of propofol infusion syndrome
- Propofol induced subacute cutaneous lupus erythematosus
- Green discoloration of urine following propofol
- Cognitive function following valve replacement surgery
- Etomidate and propofol for sedation in gastrointestinal endoscopy
- Propofol and dexmedetomidine during transcatheter aortic valve replacement (TAVR)
- Ciprofol
- Safety of ciprofol in gynecological day surgery
- Ciprofol and propofol for the induction and maintenance of general anesthesia
- Ciprofol on swallowing function in gastrointestinal endoscopy
- Remimazolam
- Special section
- Remimazolam vs propofol during cervical conization
- Remimazolam and propofol for surgical abortion
- Remimazolam tosylate and propofol in upper gastrointestinal endoscopy
- Remimazolam and propofol for ERCP
- Propofol and remimazolam on emergence profiles after general anesthesia
- Remimazolam and propofol in surgical patients
- Remimazolam and propofol in elderly patients undergoing hip replacement
- Remimazolam tosilate and propofol for day surgery
- Remimazolam and propofol for procedural sedation
- Remimazolam and Propofol on recovery of psychomotor function
- Remimazolam and propofol in patients routinely on angiotensin axis blocking drugs
- Mixed volatiles
- Emergence delirium in children
- Postoperative behavioural changes in children undergoing ambulatory procedures
- Desflurane
- Desflurane anaesthesia and the incidence of new-onset postoperative atrial fibrillation
- Brain relaxation under anaesthesia in patients undergoing craniotomy for supratentorial tumours
- Methoxyflurane
- Prehospital use of methoxyflurane
- Nitrous oxide
- Special section
- Neuropsychiatric disorders associated with recreational nitrous oxide use
- Thromboembolism with nitrous oxide misuse
- Sevoflurane
- Special section
- Sevoflurane induced neurotoxic effects on developing neurons
- Sevoflurane inhibits cholangiocarcinoma signalling
- Sevoflurane supresses hepatocellular carcinoma cell progression
- Sevoflurane suppresses the malignant progression of breast cancer
- Sevoflurane and hepatotoxicity
- Sevoflurane and malignant hyperpyrexia
- Diffuse alveolar haemorrhage following sevoflurane
- Prolonged sedation with sevoflurane in critically ill patients
- Respiratory adverse events after LMA mask removal in children
- References
- Chapter 11 Neuromuscular blocking agents and skeletal muscle relaxants
- Abstract
- Keywords
- Introduction
- Depolarizing neuromuscular blocking agents
- Succinylcholine (suxamethonium)
- Nondepolarizing neuromuscular blocking agents
- Rocuronium
- Neurotoxin
- BotulinumtoxinA
- Neuromuscular blocker reversal agents
- Sugammadex
- Skeletal muscle relaxants
- Baclofen
- Cyclobenzaprine
- References
- Chapter 12 Antihistamines (H1 receptor antagonists)
- Abstract
- Keywords
- Introduction
- Azelastine
- Bilastine
- Cetirizine
- Cyclizine
- Cyproheptadine
- Desloratadine
- Dimenhydrinate
- Diphenhydramine
- Doxylamine
- Ebastine
- Hydroxyzine
- Ketotifen
- Meclizine
- Triprolidine
- Conclusion
- References
- Chapter 13 Drugs that act on the respiratory tract
- Abstract
- Keywords
- Introduction
- Glucocorticoids
- Leukotriene modifiers
- Montelukast
- Pranlukast
- β2-Adrenoceptoragonists
- Albuterol/salbutamol
- Anticholinergic drugs
- Ipratropium
- Umeclidinium
- Anti-fibrotic therapies
- Nintedanib case reports
- Pirfenidone case reports
- Monoclonal antibodies
- Benralizumab
- Mepolizumab
- Dupilumab
- Tezepelumab
- Omalizumab
- Conclusion
- References
- Chapter 14 Positive inotropic drugs and drugs used in dysrhythmias
- Abstract
- Keywords
- Cardiac glycosides
- Digoxin
- Antidysrhythmic drugs
- Amiodarone
- Diltiazem
- Flecainide
- Lidocaine
- Mexiletine
- Propafenone
- Verapamil
- References
- Chapter 15 Clinical perspectives on adverse effects and side effects of beta adrenergic antagonists and antianginal drugs
- Abstract
- Keywords
- Introduction
- Side effects of labetalol and nifedipine during treatment of preeclampsia in Han Chinese women
- Labetalol and nicardipine precipitation with sugammadex
- Beta adrenergic antagonists
- Development and progression of chronic obstructive pulmonary disease (COPD)
- Adverse events in patients taking non-selective beta blockers (BBs) for variceal bleed prophylaxis
- Hypotension and bradycardia during BB treatment following acute coronary syndrome (ACS)
- Bisoprolol
- Carteolol
- Carvedilol
- Esmolol
- Labetalol
- Metoprolol
- Nebivolol
- Propranolol
- Timolol
- Calcium channel blockers
- Genetic risk factors for side effects
- Drug–drug interactions with non-vitamin K antagonist anticoagulants (NOACs)
- Amlodipine
- Diltiazem
- Nicardipine
- Nifedipine
- Calcium channel blocker and nirmatrelvir/ritonavir drug–drug interactions
- Inhibitors of fatty acid oxidation
- Trimetazidine
- Nitrates
- Amyl nitrate
- Acknowledgements
- References
- Chapter 16 Drugs acting on the cerebral and peripheral circulations
- Abstract
- Keywords
- Introduction
- Drugs used in the treatment of migraine
- Sumatriptan
- Takotsubo syndrome
- Bone site fracture pain
- Dihydroergotamine
- Erenumab
- Drugs used in the treatment of peripheral vascular disease
- Drugs used in the treatment of erectile dysfunction
- Peripheral vasodilators
- Dipyridamole-induced ST elevation myocardial infarction
- Peripheral vasoconstrictors
- Topical epinephrine
- Drugs used in the treatment of pulmonary arterial hypertension
- Epoprostenol
- Treprostenil
- Conclusion
- References
- Chapter 17 Side effects of antihypertensive drugs
- Abstract
- Keywords
- Introduction
- Angiotensin-converting enzyme inhibitors
- Respiratory
- Vascular
- Vascular/gastrointestinal
- Gastrointestinal
- Hemodynamic (overdose)
- Angiotensin II receptor blockers
- Gastrointestinal
- Vascular (overdose)
- Calcium channel blockers
- Hemodynamic (overdose)
- Cardiac
- Cardiac (overdose)
- Cardiac/hepatic (overdose)
- Pulmonary renal (overdose)
- Vascular
- Hematologic
- Respiratory
- Musculoskeletal
- Maxilofacial
- Thiazide diuretics
- Dermatologic
- Electrolyte abnormalities
- Loop diuretics
- Auditory
- Dermatologic
- Electrolyte abnormalities
- Renal
- Hematologic
- Gastrointestinal
- Hydralazine
- Vascular (pulmonary/renal)
- Renal
- Alpha blockers
- Neuro-vascular
- Conclusion
- References
- Further reading
- Chapter 18 Clinical studies on the adverse effects of diuretics
- Abstract
- Keywords
- Introduction
- Aldosterone receptor antagonists
- Eplerenone
- Esaxerenone
- Spironolactone
- Carbonic anhydrase inhibitors
- Acetazolamide
- Methazolamide
- Loop diuretics
- Furosemide
- Torsemide
- Thiazide and thiazide-like diuretics
- Hydrochlorothiazide
- Chlorthalidone
- Indapamide
- Serious life-threatening adverse effects with most diuretics
- Conclusion
- References
- Chapter 19 Recent clinical studies on metals and metal antagonists
- Abstract
- Keywords
- Aluminum
- Cardiovascular
- Ammonium tetrathiomolybdate
- Arsenic
- Cadmium
- Cobalt
- Cardiac
- Immunologic
- Deferasirox, deferiprone, and deferoxamine combinatorial therapies
- Susceptibility factors
- Deferasirox
- Tolerability
- Susceptibility factors
- Deferiprone
- Urinary tract
- Susceptibility factors
- Deferoxamine
- Nervous system
- Kidney
- Heavy metal toxicity
- Hydroxyurea and other fetal hemoglobin inducers
- Skin and nails
- Musculoskeletal
- Immunologic
- Long-term effects
- Suscpetibility factors
- Physiological factors
- Iron
- Gastrointestinal
- Liver
- Susceptibility factors
- Iron chelators
- Sensory systems
- Lead
- Susceptiblity factors
- Lithium
- Neurological
- Magnesium
- Manganese
- Microplastics
- d-Penicillamine
- Skin
- Kidney
- Immunologic
- Suscpetibility factors
- Platinum
- Ear, nose, and throat
- Selenium
- Sensory system
- Hair nails
- Polystyrene sulphonates and patiromer
- Gastrointestinal
- Potassium chelator comparisons
- Sodium zirconium cyclosilicate
- Thallium
- TDMQ20
- References
- Chapter 20 Side effects of antiseptic drugs and disinfectants
- Abstract
- Keywords
- Introduction
- Special review: Antiseptic drugs and disinfectants during COVID-19
- Alcohols
- Aldehydes
- Formaldehyde
- Glutaraldehyde (glutaral)
- Benzalkonium compounds
- Ethylene oxide
- Guanidines
- Chlorhexidine
- Polyhexamethylene guanidine
- Polyhexamethylene biguanidine
- Halogens
- Sodium hypochlorite
- Triclosan
- Polyvinylpyrrolidone (povidone)-iodine
- Sulfites
- Isothiazolinones
- Ultraviolet (UV) light
- Conclusion
- References
- Chapter 21 Side effects of novel combination beta lactam/beta lactamase inhibitors
- Abstract
- Keywords
- Introduction
- Ceftazidime/avibactam (CZA)
- Neutropenia
- Acute kidney injury
- Central nervous system
- Ceftolozane/tazobactam (C/T)
- Hypokalemia
- Blood dyscrasias
- Central nervous system
- Cefiderocol (CFDC)
- Urine discoloration
- Meropenem/vaborbactam (M/V)
- Hypokalemia
- Imipenem/cilastatin/relebactam (IMI/REL)
- Elevated liver enzymes
- Renal toxicity
- Neurotoxicity
- Conclusion
- References
- Chapter 22 Side effects of miscellaneous antibiotics
- Abstract
- Keywords
- Introduction
- Glycopeptides
- Dalbavancin
- Telavancin
- Oritavancin
- Vancomycin
- Oxazolidinones
- Linezolid
- Macrolides
- Azithromycin
- Clarithromycin
- Lincosamides
- Clindamycin
- Fluoroquinolones
- Ciprofloxacin
- Levofloxacin
- Moxifloxacin
- Ofloxacin
- Norfloxacin
- Aminoglycosides
- Amikacin
- Gentamicin
- Tobramycin
- Streptomycin
- Miscellaneous
- Metronidazole
- Nitrofurantoin
- Sulfamethoxazole/trimethoprim (SMX-TMP)
- Daptomycin
- Conclusion
- References
- Chapter 23 Recent clinical studies on side effects of antiprotozoal and antiparasitic drugs
- Abstract
- Keywords
- Introduction
- Atovaquone
- Tinidazole
- Sulfadoxine–Pyrimethamine
- Primaquine
- Albendazole
- Artemether-lumefantrine, mefloquine and atovaquone-proguanil
- Metronidazole-induced cardiotoxicity in albino mice
- Potential metronidazole-induced mania
- Metronidazole-induced encephalopathy (MIE)
- Allergic contact dermatitis to metronidazole
- Hydroxychloroquine-induced cardiotoxicity
- Conclusion
- References
- Chapter 24 Side effects of anti-fungal medications with an emphasis on amphotericin B, posaconazole, and voriconazole
- Abstract
- Keywords
- Introduction
- Allylamines
- Terbinafine
- Azoles
- Clotrimazole
- Fluconazole
- Itraconazole
- Posaconazole
- Terconazole
- Voriconazole
- Polyenes
- Amphotericin B deoxycholate
- Amphotericin B liposomal
- Others
- Griseofulvin
- Conclusion
- References
- Chapter 25 Recent perspectives on adverse effects of clinically relevant antiviral drugs
- Abstract
- Keywords
- Introduction
- Drugs active against cytomegalovirus (CMV)
- Ganciclovir
- Ganciclovir/valganciclovir
- Valganciclovir/maribavir
- Foscarnet
- Maribavir
- Letermovir
- Drugs active against hepatitis C virus (HCV)
- Glecaprevir/pibrentasvir
- Elbasvir/grazoprevir
- Ledipasvir/sofosbuvir
- Sofosbuvir/velpatasvir
- Sofosbuvir/velpatasvir/voxilaprevir
- Drugs active against hepatitis B virus (HBV)
- Interferon-2α
- Entecavir
- Tenofovir disoproxil fumarate
- Tenofovir alafenamide
- Drugs active against herpes simplex virus-1, -2 (HSV-1, HSV-2)
- Acyclovir
- Foscarnet
- Valacyclovir
- Drugs active against human immunodeficiency virus (HIV): Integrase inhibitors (INSTIs)
- Abacavir
- Bictegravir
- Cabotegravir
- Dolutegravir
- Drugs active against human immunodeficiency virus (HIV): Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
- Drotaverine
- Efavirenz
- Rilpivirine
- Drugs active against human immunodeficiency virus (HIV): Nucleoside/-tide reverse transcriptase inhibitors (NRTIs)
- Tenofovir alafenamide
- Tenofovir disoproxil fumarate
- Drugs active against human immunodeficiency virus (HIV): Protease inhibitors (PIs)
- Darunavir
- Drugs active against coronavirus disease 2019
- Remdesivir
- Nirmatrelvir/ritonavir (Paxlovid)
- Drugs active against influenza virus
- Oseltamivir/zanamivir
- Conclusion
- References
- Chapter 26 Vaccines
- Abstract
- Keywords
- Viral vaccines
- COVID-19/SARS-CoV-2
- Dengue vaccine
- Ebola vaccine
- Hepatitis B vaccine
- Human papillomavirus vaccine
- Influenza vaccine
- Measles–mumps–rubella and measles–mumps–rubella-varicella vaccine
- Mpox vaccine
- Rabies virus vaccine
- Rotavirus vaccine
- Respiratory syncytial virus vaccines
- Varicella/herpes zoster vaccine
- Susceptibility factors
- Bacterial vaccines
- Bacillus Calmette–Guerin vaccines
- Meningococcal vaccines
- Pertussis vaccines (including diphtheria–tetanus–acellular/whole-cell pertussis-containing vaccines)
- Pneumococcal vaccines
- Parasitic vaccines
- Malaria vaccine
- Cancer vaccines
- Solid tumor vaccines
- Cross references
- References
- Chapter 27 Blood and blood treatments
- Abstract
- Keywords
- Introduction
- Oncology therapies
- Bispecific monoclonal antibodies
- Monoclonal antibodies
- Immune checkpoint inhibitors
- Kinase inhibitor
- Small molecule kinase inhibitor
- Proteasome inhibitor
- FL3T inhibitor
- Human cytomegalovirus promoter
- Pediatric chemotherapy regimen
- Non-oncological therapies
- Integrase inhibitor
- Oral small molecule inhibitor
- Competitive inhibitor
- Erythroid-maturating agent
- Platelets and cryoprecipitate
- Conclusion
- References
- Chapter 28 Side effects of drugs that affect blood coagulation, fibrinolysis, and hemostasis
- Abstract
- Keywords
- Introduction
- Warfarin and direct acting oral anticoagulants (DOACS)
- Bleeding risk in AF (comparative studies)
- Pulmonary
- Apixaban
- Subdural hematoma and other bleeding events
- Apixaban-related complications
- Nephropathy
- Small vessel vasculitis
- Atrial arrhythmias (AA)
- Dermatologic effects
- Safety comparisons
- Asundexian
- Overall safety profile
- Dabigatran
- Drug–drug interaction
- Hemorrhagic complications
- Rivaroxaban
- Anaphylaxis
- Dermatologic
- Liver injury
- Bleeding events
- Pharmacokinetic effects
- Warfarin
- Hemorrhage and hematoma
- Anemia secondary to warfarin overdose
- Bleeding event
- Pharmacogenomic effects
- Increased risk of epilepsy in AF
- Parenteral anticoagulants
- Low molecular weight heparins (LMWH)
- Enoxaparin
- Bullous hemorrhagic lesions
- Hemorrhage and hematoma
- Unfractionated heparin
- Heparin-induced thrombocytopenia (HIT)
- DRESS syndrome
- Cancer-associated thrombosis (CAT)
- Nafamostat mesylate
- Phlebitis
- Prothrombotic agents
- TXA
- Thrombosis
- Anticoagulant reversal agents
- Andexanet alfa
- Thrombolytic agents
- Alteplase
- Conclusion
- References
- Chapter 29 Clinical studies on adverse effects of gastrointestinal drugs
- Abstract
- Keywords
- Acid-suppression agents
- Proton pump inhibitors
- Omeprazole
- Esomeprazole
- Omeprazole
- Potassium competitive acid blocker
- Vonoprazan
- Special review
- Cathartics, laxatives, and prokinetic agents
- Antiemetic agents
- Anti-inflammatory agents
- Aminosalicylates
- Thiopurines
- Miscellaneous GI agents
- Adalimumab
- Golimumab
- Infliximab
- Teduglutide
- Tofacitinib
- References
- Chapter 30 Recent clinical studies on the side effects of agents that influence corticotrophins, corticosteroids, and prostaglandins
- Abstract
- Keywords
- Introduction
- Corticotrophins
- Systemic glucocorticoids
- Endocrine
- Nephrology
- Neurological
- Neurologic/cardiovascular
- Ocular
- Psychological
- Systemic (multi-organ system)
- Cardiovascular
- Dermatological
- Electrolyte disturbances
- Musculoskeletal
- Ophthalmologic
- Skeletal
- Prostaglandins and analogues
- Cardiovascular
- Misoprostol
- Dermatology
- Endocrine
- Hepatotoxicity
- Conclusion
- References
- Chapter 31 Sex hormones, related compounds, and hormonal contraceptives including miscellaneous hormones
- Abstract
- Keywords
- Introduction
- Second generation androgen receptor antagonists
- Abiraterone acetate
- Apalutamide
- Enzalutamide
- Estrogen receptor antagonists
- Fulvestrant
- Gonadotropin-releasing hormone agonists
- Leuprolide
- Triptorelin
- Aromatase inhibitors
- Exemestane
- Letrozole
- Anastrozole
- Selective estrogen receptor modulators
- Raloxifene
- Tamoxifen
- Toremifene
- Clomifene
- Progestins
- Nomegestrol acetate
- Desogestrel
- Gestodene
- Estrogens
- Ethinyl estradiol
- Estradiol valerate
- Hormonal contraceptives
- Depot medroxyprogesterone acetate
- Etonogestrel
- Levonorgestrel
- Norethindrone (norethisterone)
- Combined oral contraceptives
- Yasmin
- Lo Loestrin Fe
- Gestodene/ethinylestradiol
- Algestone/estradiol
- Ethinylestradiol/desogestrel or drospirenone
- Testosterone replacement therapy
- Intracranial hypertension
- Cardiovascular death
- Central serous chorioretinopathy
- Pulmonary embolisms and deep vein thrombosis
- Anabolics, androgens, and related compounds
- Subclavian artery occlusion
- Neuropsychiatric disturbances
- Drug-induced liver injury
- Drug-induced liver injury and renal necrosis
- Ischemic stroke
- Drug-induced hypothyroidism
- Recombinant human growth hormones
- Optic nerve morphology
- Ergot alkaloids
- Methylergometrine (methylergonovine, methergine)
- Oxytocin
- Oxytocin-induced hypersensitivity
- Uterine rupture
- Conclusion
- Acknowledgments
- References
- Chapter 32 Side effects of thyroid hormones, iodine, iodides, and antithyroid medications
- Abstract
- Keywords
- Introduction
- Thyroid hormones
- Levothyroxine (T4)
- Liothyronine
- Thyroid, desiccated
- Thionamides
- Carbimazole (CMZ)
- Methimazole (MMI)
- Propylthiouracil (PTU)
- Radioactive iodine (RAI)
- Conclusion
- References
- Chapter 33 Side effects of medications used in the management of diabetes
- Abstract
- Keywords
- Introduction
- Insulin and associated adverse effects (see Fig. 2)
- Amyloidosis (localized)
- Anaphylaxis
- Cardiac hypertrophy
- Edema
- Erythrodermic psoriasis
- Hypersensitivity
- Nausea
- Panniculitis
- Soft tissue infection
- Urticarial vasculitis
- Other antihyperglycemic drugs (see Fig. 3)
- Metformin
- Glucagon-like peptide-1 agonists
- Dulaglutide
- Liraglutide
- Semaglutide
- Tirzepatide (Monjaro®)
- DPP-4 inhibitors
- Alogliptin
- Linagliptin
- Sitagliptin
- Sodium glucose transporter-2 (SGLT-2) inhibitors
- Empagliflozin
- Pancreatitis
- Conclusion
- References
- Chapter 34 Side effects of anti-lipid medications
- Abstract
- Keywords
- Introduction
- HMG-COA reductase inhibitors
- Rhabdomyolysis
- Dermatologic
- Ophthalmologic
- PCSK9 inhibitors
- Muscle related
- Neurocognitive
- Psychiatric
- Female reproductive disorders
- Bile acid sequestrants
- Cholestyramine
- Colestipol
- Colesevelam
- Fibric acid derivatives
- Gemfibrozil/Fenofibrate
- Omega-3 fatty acids/icosapent ethyl
- Niacin
- Bempedoic acid
- Ezetimibe
- References
- Chapter 35 Case studies on adverse effects of drugs used in ocular treatment
- Abstract
- Keywords
- Introduction
- Anti-VEGF
- Medications used to treat glaucoma
- Prostaglandins (PGF 2α) analogues
- EP2-receptor-selective agonist ocular hypotensives
- Beta blockers
- Carbonic anhydrase inhibitors
- Sympathetic alpha 2-receptor antagonists
- Rho kinase (ROCK) inhibitors
- Ophthalmic anti-inflammatory agents
- Corticosteroids
- Immunomodulating agents
- Anti-microbials
- Sulfonamides
- Fluoroquinolones
- Medications used to treat dry eye
- Cholinergic agonists
- Special topics in complement inhibition for treatment of geographic atrophy
- Complement inhibitors
- Conclusion
- References
- Chapter 36 Adverse drug reactions and adverse drug events associated with use of antidepressant, antihypertensive, antidiabetic, and antibiotic drugs in pregnancy
- Abstract
- Keywords
- Introduction
- Antidepressants
- SSRI's and SNRI's
- Other antidepressants
- Antidiabetic drugs
- Glucagon-like peptide-1 (GLP-1) agonists and SGLT2i's
- Metformin and insulin
- Sulfonylureas
- Antihypertensive drugs
- All classes
- Beta-blockers
- Methyldopa
- Nifedipine, labetalol, hydralazine
- Diuretics
- Antibiotics
- All classes
- Penicillins
- Tetracyclines
- Macrolides
- Miscellaneous antibiotics
- Conclusion
- References
- Chapter 37 Adverse effects, side effects and toxicity of select phytochemicals: A review of clinical studies
- Abstract
- Keywords
- Introduction
- Amygdalin
- Apigenin
- Caffeic acid
- Capsaicin
- Curcumin
- Ferulic acid
- Fisetin
- Gallic acid
- Genistein
- Gingerol
- Ginsenosides
- Hypericin
- Yohimbine
- Ginkgolides and bilobalide
- References
- Chapter 38 Development of resistance to anticancer medications: Challenges and clinical implications
- Abstract
- Keywords
- Introduction
- Taxanes
- Paclitaxel
- Nab-paclitaxel
- Docetaxel
- Cabazitaxel
- Epothilones
- Ixabepilone
- Patupilone
- Colchicine
- Anthracyclines
- Doxorubicin
- Idarubicin
- Epirubicin
- Alkylating agents
- Cyclophosphamide
- Thalidomide derivatives
- Lenalidomide
- Bleomycin (antitumor antibiotic)
- Etoposide (podophyllotoxins)
- Topotecan and irinotecan (topoisomerase inhibitors)
- Tamoxifen (hormonals)
- Methotrexate (antimetabolites)
- Hydroxyurea
- Conclusion
- References
- Chapter 39 Side effects of radiocontrast agents and radiopharmaceuticals
- Abstract
- Keywords
- Introduction
- Iodine-based contrast agents (ICAs)
- ICA-induced neurotoxicity
- ICA-induced thyroid dysfunction
- ICA-induced kidney injury in cardiac patients
- Contrast-induced extravasation
- ICA-induced hypersensitivity reactions
- ICA-induced stress on mononuclear cells in vitro
- Gadolinium-based contrast agents (GBCAs)
- GBCA-induced nephrogenic systemic fibrosis (NSF)
- GBCA-induced hypersensitivity reactions
- GBCA safety during pregnancy
- Iron-oxide contrast agents
- Ferumoxytol-induced adverse events
- Barium-sulfate and other oral/GI contrast agents (non-iodinated)
- Barium-induced cognitive impairment
- Barium-induced peritonitis
- Radiopharmaceuticals
- Actinium-225 (225Ac)
- Iodine-125 (125I)
- Iodine-131 (131I)
- Lutetium-177 (177Lu)
- Radium-223 (223Ra)
- Yttrium-90 (90Y)
- Rhenium-188 (188Re)
- Conclusion
- References
- Chapter 40 Central nervous system stimulants and drugs that suppress appetite
- Abstract
- Keywords
- Introduction
- Myocardial infarction
- Amphetamine and amphetamine derivatives (Bello & Kshatriya, 2019) [R]; (Kshatriya & Bello, 2020) [R]; Scarpa et al., 2021) [R]
- Organs and systems
- Ecstasy (3,4-methylenedioxy-N-methylamphetamine; MDMA) (Bello & Kshatriya, 2019) [R]; (Kshatriya & Bello, 2020) [R]; (Scarpa et al., 2021) [R]
- Organs and systems
- Methylphenidate (Bello & Kshatriya, 2019) [R]; (Kshatriya & Bello, 2020) [R]; Scarpa et al., 2021) [R]
- Organs and systems
- Selective norepinephrine reuptake inhibitors
- Atomoxetine (Bello & Kshatriya, 2019) [R]; (Kshatriya & Bello, 2020) [R]; (Scarpa et al., 2021) [R]
- Vigilance promoting drugs
- Modafinil and armodafinil (Bello & Kshatriya, 2019) [R]; (Kshatriya & Bello, 2020) [R]; (Scarpa et al., 2021) [R]
- Drugs that suppress appetite
- GLP-1 (glucagon-like peptide-1) analogs
- Liraglutide
- Gastrointestinal
- Semaglutide
- Skin
- Oral
- Nervous system
- Phentermine (Bello & Kshatriya, 2019) [R]; (Kshatriya & Bello, 2020) [R]; (Scarpa et al., 2021) [R]
- Organs and systems
- Phentermine/topiramate
- Organ and systems
- Parasympathomimetics
- Donepezil (Bello & Kshatriya, 2019) [R]; (Kshatriya & Bello, 2020) [R]; Scarpa et al., 2021) [R]
- Memantine (Bello & Kshatriya, 2019) [R]; (Kshatriya & Bello, 2020) [R]; (Scarpa et al., 2021) [R]
- Organs and systems
- Rivastigmine (see Bello & Kshatriya, 2019) [R]; (Kshatriya & Bello, 2020) [R]; (Scarpa et al., 2021) [R]
- Organs and systems
- Caffeine (Bello & Kshatriya, 2019) [R]; (Kshatriya & Bello, 2020) [R]; Scarpa et al., 2021) [R]
- Conclusion
- References
- Index of Drugs
- Index of Drug-Drug Interactions
- Index of Adverse Effects and Adverse Reactions
- No. of pages: 1052
- Language: English
- Edition: 1
- Volume: 46
- Published: November 20, 2024
- Imprint: Elsevier
- Hardback ISBN: 9780443294464
- eBook ISBN: 9780443294471
SR
Sidhartha D. Ray
Sidhartha D. Ray, PhD, FACN serves as a Senior Professor of Pharmaceutical and Biomedical Sciences at The Touro College of Pharmacy at Manhattan, New York. Prior to this he served as Professor of Pharmaceutical Sciences for nearly 2 decades at the Arnold & Marie Schwartz College of Pharmacy and Health Sciences of Long Island University, New York, and as the founding chair of Pharmaceutical Science department at Manchester University College of Pharmacy, Indiana, USA. He has been in the health sciences academy for over 35 years mainly focusing on pharmacy teaching, research and service. Dr. Ray's research program focus on drug & chemical induced organ toxicology, mechanistic & molecular toxicology, adverse drug reaction mechanisms, side effects of a number of therapeutically relevant drugs and environmentally significant chemicals. Over the last two decades, Dr. Ray’s seminal discoveries have provided clear understandings on the dynamic role of apoptosis, necrosis and necraptosis during organotoxic reactions and have influenced the development of safety measures for a stunning variety of xenobiotics, phytochemicals and nutraceuticals. He is internationally recognized as a leader in the scientific community and was one of the front runners in exploring mechanisms of drug and chemical-induced programmed and un-programmed cell death in in-vivo models. His landmark studies on the interplay of bcl-2, bcl-xl, p53, bad and bax during acetaminophen induced cell death and its prevention by grape seed proanthocyanidin extract has earned worldwide citations. His peer recognition and acknowledged service contributions are reflected by his election into multiple international professional organizations, such as the Society of Toxicology (SOT), Society of Free Radical Biology & Medicine (SFRBM), American Society of Pharmacology & Experimental Therapeutics (ASPET), American Association of Colleges of Pharmacy (AACP) and American College of Nutrition (ACN). Dr. Ray is an Associate Editor of Encyclopedia of Toxicology (3rd Ed, Elsevier, 2014), and serves on the editorial boards of multiple prestigious international journals, including ‘Archives of Toxicology’ and ‘Oxidative Medicine & Cellular Longevity’.
Based on his contributions to teaching, service and scholarship to health sciences in general, Dr. Ray received multiple prestigious awards, inc. the American Academy of Clinical Toxicology’s national research award (1996), ‘Fellow of the American College of Nutrition’ honor in 1999, David Newton Award for Excellence in Teaching Pharmacy (2005), the Biennial Abraham Krasnoff Memorial Award for Lifetime Scholarly Achievement (2008), Arnold & Marie Schwartz College of Pharmacy & Health Science’s ‘Wall-of-Fame’ honor (2011), the Society of Toxicology’s ‘Undergraduate Educator of the Year’ national award (2013), and the Manchester University’s ‘Outstanding Scholar of the Year’ award (2014). He currently serves on the SOT-NIH–NLM’s joint Toxlearn Project, SOT Undergraduate Task Force (2007 – present), and has previously served on the SOT’s Education Committee (2007 – 2010). In his lifetime, Dr. Ray has mentored research to numerous PharmD, MS, MD and PhD students in a number of areas of toxicology and biomedical sciences, made seminal contributions to the fields of pharmacology, toxicology, free radical biology, anticancer mechanism, phytochemicals, nutraceuticals & dietary supplements, and molecular safety sciences. Dr. Ray loves to promote ‘Lifelong Learning’ strategies to his students and clearly models his beliefs day in and day out. Visit URL: www.sidhartharay.com/ for more details.
Affiliations and expertise
Senior Professor of Pharmaceutical and Biomedical Sciences, Touro College of Pharmacy, Touro University System, Manhattan, NY, USARead Side Effects of Drugs Annual on ScienceDirect